SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants

SB 9200 is a novel, first-in-class oral modulator of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. SB 9200 has broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus and influenza an...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Med Virol
Main Authors: Jones, Meleri, Cunningham, Morven E., Wing, Peter, DeSilva, Sampath, Challa, Rupa, Sheri, Anjaneyulu, Padmanabhan, Seetharamaiyer, Iyer, Radhakrishnan P., Korba, Brent E., Afdhal, Nezam, Foster, Graham R.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5513743/
https://ncbi.nlm.nih.gov/pubmed/28303593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.24809
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares